Sam Klempner, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment strategies for esophageal, GE junction, and gastric cancers.
Atembimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
Atembimetinib with gemcitabine and nab-paclitaxel achieved a 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.
Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC
At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies
Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors
An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.